Carroll Patrick Harrison, the Chief Medical (TASE:PMCN) Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold 4,707 shares of the company's Class A common stock. The transaction, which took place on November 11, 2024, was executed at a price of $28.24 per share, amounting to a total sale value of approximately $132,925. Following this transaction, Harrison retains ownership of 192,234 shares in the company.
In other recent news, Hims & Hers Health, Inc. has demonstrated significant financial growth with a 77% year-over-year increase in third-quarter sales, surpassing $400 million. The company's adjusted EBITDA also grew significantly, reaching over $50 million, indicating a healthy 13% margin. Several firms, including Piper Sandler, Needham, TD Cowen, Citi, Truist Securities, and BofA Securities, have updated their outlooks on the company. Hims & Hers also reported plans to increase marketing expenditures in Q4 and to launch liraglutide, the first generic GLP-1, in 2025. The company is forecasting Q4 2024 revenue between $465 million and $470 million, marking an 89% to 91% year-over-year increase. The full-year revenue is projected to be between $1.46 billion and $1.465 billion, reflecting a 67% to 68% increase. These are recent developments in the company's operations.
InvestingPro Insights
As Hims & Hers Health, Inc. (NYSE:HIMS) experiences insider selling activity, it's crucial to consider the broader financial context of the company. According to InvestingPro data, HIMS has demonstrated remarkable growth, with a staggering 199.89% year-to-date price total return as of the latest available data. This impressive performance is further underscored by the company's robust revenue growth of 56.7% over the last twelve months, reaching $1.24 billion.
InvestingPro Tips highlight that HIMS has been profitable over the last twelve months, with analysts expecting net income to grow this year. This positive outlook is supported by the fact that four analysts have revised their earnings upwards for the upcoming period, suggesting confidence in the company's financial trajectory.
Despite the recent insider sale, it's worth noting that HIMS operates with a moderate level of debt and its liquid assets exceed short-term obligations, indicating a solid financial position. The company's strong performance is reflected in its market capitalization of $6.04 billion, positioning it as a significant player in the healthcare technology sector.
For investors seeking a more comprehensive analysis, InvestingPro offers 18 additional tips for HIMS, providing a deeper understanding of the company's financial health and market position. These insights could be particularly valuable given the recent insider activity and the company's rapid growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.